|
Name |
xerucitrinic acid A
|
Molecular Formula | C27H32O8 | |
IUPAC Name* |
6,8,11'-trihydroxy-4,4',5,6',7,8',10'-heptamethylspiro[1,4-dihydroisochromene-3,3'-2,6-dioxatricyclo[7.3.1.05,13]trideca-1(12),9(13),10-triene]-12'-carboxylicacid
|
|
SMILES |
Cc1c(O)c(C)c2c(c1O)COC1(CC3(C)OC(C)C(C)c4c(C)c(O)c(C(=O)O)c(c43)O1)C2C
|
|
InChI |
InChI=1S/C27H32O8/c1-10-15(6)34-26(7)9-27(35-24-19(25(31)32)23(30)11(2)17(10)20(24)26)14(5)18-12(3)21(28)13(4)22(29)16(18)8-33-27/h10,14-15,28-30H,8-9H2,1-7H3,(H,31,32)/t10-,14+,15-,26-,27+/m1/s1
|
|
InChIKey |
WPSWXZLKQCPIGV-HBNYTQNUSA-N
|
|
Synonyms |
NA
|
|
CAS | NA | |
PubChem CID | NA | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 484.55 | ALogp: | 5.0 |
HBD: | 4 | HBA: | 7 |
Rotatable Bonds: | 1 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 125.7 | Aromatic Rings: | 5 |
Heavy Atoms: | 35 | QED Weighted: | 0.428 |
Caco-2 Permeability: | -5.406 | MDCK Permeability: | 0.00000929 |
Pgp-inhibitor: | 0.17 | Pgp-substrate: | 0.292 |
Human Intestinal Absorption (HIA): | 0.532 | 20% Bioavailability (F20%): | 0.013 |
30% Bioavailability (F30%): | 0.006 |
Blood-Brain-Barrier Penetration (BBB): | 0.015 | Plasma Protein Binding (PPB): | 100.43% |
Volume Distribution (VD): | 0.267 | Fu: | 1.91% |
CYP1A2-inhibitor: | 0.011 | CYP1A2-substrate: | 0.972 |
CYP2C19-inhibitor: | 0.012 | CYP2C19-substrate: | 0.745 |
CYP2C9-inhibitor: | 0.105 | CYP2C9-substrate: | 0.174 |
CYP2D6-inhibitor: | 0.012 | CYP2D6-substrate: | 0.121 |
CYP3A4-inhibitor: | 0.076 | CYP3A4-substrate: | 0.202 |
Clearance (CL): | 4.012 | Half-life (T1/2): | 0.419 |
hERG Blockers: | 0.005 | Human Hepatotoxicity (H-HT): | 0.724 |
Drug-inuced Liver Injury (DILI): | 0.983 | AMES Toxicity: | 0.1 |
Rat Oral Acute Toxicity: | 0.771 | Maximum Recommended Daily Dose: | 0.048 |
Skin Sensitization: | 0.856 | Carcinogencity: | 0.216 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.462 |
Respiratory Toxicity: | 0.247 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC000945 | 0.352 | D0FX2Q | 0.256 | ||||
ENC003996 | 0.339 | D0WY9N | 0.248 | ||||
ENC003995 | 0.339 | D0G3DL | 0.241 | ||||
ENC003994 | 0.339 | D06XZW | 0.234 | ||||
ENC002391 | 0.333 | D04ITO | 0.229 | ||||
ENC003148 | 0.324 | D05CHI | 0.229 | ||||
ENC004969 | 0.324 | D0G9IU | 0.227 | ||||
ENC002307 | 0.315 | D01XWG | 0.225 | ||||
ENC002859 | 0.310 | D01XDL | 0.217 | ||||
ENC004137 | 0.303 | D0G4OD | 0.216 |